Rising Prevalence Of Nosocomial Infection Is The Major Driving Factor For Hospital Acquired Disease Testing Market

According to a recently published report by Brisk Insights, the Global Hospital Acquired Disease Testing Market is expected to grow at the CAGR of 5.9% during 2017-2025. The global hospital acquired disease testing market is segmented on the basis of infection type and geography. The report on global hospital acquired disease testing market forecast 2017-2025 (by infection type and geography) provides a detailed overview and predictive analysis of the market.

Full report available on Global Hospital Acquired Disease Testing market: Global Industry Size, Growth, Share and Forecast to 2025 report at http://www.briskinsights.com/report/hospital-acquired-disease-testing-market

Market Insights

Hospital infection also known as nosocomial infection, is the infection acquired by patient during the stay in hospital, which was previously not observed. The infection is acquired due to immune compromised patient, prolonged stay in hospital, hospital or staff negligence in carrying out procedure or maintaining the hygiene. According to a survey 9.2 patients from 100 in the U.S. suffer from hospital infection. Nowadays, nosocomial infection is commonly observed which is adding up to the burden of mortality and morbidity of hospital and increase in cost pressure. Thus stringent regulation and guidelines are coming up with respect to hospital hygiene and standard protocol to be followed, which acts main driver for the nosocomial infection market.

Scope of the report

1. Global Hospital Acquired Disease Testing Market, by Infection Type, 2015–2025 ($ Million)

1.1. Pneumonia
1.2. Urinary Tract Infection
1.3. Blood Stream Infection
1.4. Surgical Site Infection
1.5. MRSA
1.6. Others

2. Global Hospital Acquired Disease Testing Market, by Geography, 2015-2025 ($ Million)

2.1. North America (U.S. & Canada)
2.2. Europe (U.K., Germany & Rest of Europe)
2.3. Asia Pacific (China, Japan, and Rest of APAC)
2.4. Latin America (Brazil, Mexico and Rest of LATAM)                  
2.5. Middle East and Africa (UAE, Saudi Arabia, South Africa)

Full report available on Global Hospital Acquired Disease Testing market: Global Industry Size, Growth, Share and Forecast to 2025 report at http://www.briskinsights.com/report/hospital-acquired-disease-testing-market

3. Profiles

3.1. Becton Dickinson
3.2. BioMerieux
3.3. Cepheid Inc
3.4. Cantel Medical Corp.
3.5. Qiagen
3.6. Diatherix Laboratories
3.7. Roche Holding AG
3.8. Nordion Inc
3.9. Others

About Brisk Insights:

Brisk Insights is a global market research firm. Our insightful analysis is focused on developed and emerging markets. We identify trends and forecast markets with a view to aid businesses identify market opportunities   optimize strategies. Our team of 200 analysts’ provides enterprises with strategic insights. Brisk Insights works to help enterprises grow through strategic insights and actionable solutions.

For More Details:

Contact Person: Jennifer Smith

Phone: +448081890034

Address: Office 1094 109 Vernon House Friar Lane Nottingham NG1 6DQ UK

Email: sales@briskinsights.com

Web: http://www.briskinsights.com

Market Analysis,Competitive landscape & Depth Report of Hospital Acquired Disease Testing 2016

Hospital Acquired Disease Testing Market Forecast And opportunities Trends, Size, Drivers 2016 to 2022 – Credence Research 

According to the latest report published by Credence Research, Inc. “Hospital Acquired Disease Testing Market Growth, Future Prospects and Competitive Analysis, 2016-2022,” the  hospital acquired disease testing market was valued at USD 523.0 Mn in 2015, and is expected to reach USD 1,630.0 Mn by 2022, expanding at a CAGR of 5.4% from 2016 to 2022.

For More Information, List of Figure, Tables And TOC Visit http://www.credenceresearch.com/report/hospital-acquired-disease-testing-market 

Market Insights

Hospital acquired infections/diseases (HAIs) or nosocomial infections  are defined to the infection acquired by patients during their stay in healthcare settings. Approximately 9.2 out of 100 patients in the U.S. acquire HAI. The most common types of HAIs include pneumonia, urinary tract infection, bloodstream infection, surgical site infection and others. HAIs are caused by pathogens among patients with compromised immune system, and negligence by hospital staff. The significant morbidity and mortality, the associated management costs and growing pressure from governing bodies have urged care-givers to devise accurate diagnosis of HAIs for efficient healthcare provision.

Download PDF Sample Report @ http://www.credenceresearch.com/sample-request/57814

The global hospital acquired disease testing market is categorized into tests for hospital acquired pneumonia, urinary tract infection, surgical site infection, bloodstream infection, MRSA and others. Hospital acquired pneumonia and urinary tract infection together occupy more over 50% market share in 2015 with a larger set of revenue coming from urinary tract infection. The prevalence and morbidity associated with urinary tract infection is the highest among the other infection types and its diagnosis is the swiftest. It is anticipated that the dominance of this segment will continue through the forecast period 2016-2022. Other testing tools for surgical site infections and bloodstream infection are anticipated to undergo faster growth during the forecast period attributed by their alarming incidence in the emerging markets.

Geographically, North America is the largest regional market for hospital acquired  disease testing, high number of hospital stays and the corresponding risk of contracting HAIs majorly determine the market size of this region. On the other hand, greater awareness and reducing the incidence of hospital readmission, along with the growing urgency to control hospital and healthcare costs contribute to the faster market growth rate of Asia-Pacific and Latin America hospital acquired disease testing markets.

In view of the market competition, this market is fragmented with a multitude of companies offering HAI testing tools. Some of the notable players in the hospital acquired disease testing market include Diatherix Corp, Roche, Cantel Medical Corporation, Qiagen, Cephid, bioMeriux and others.

About Us: 

Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.

Media Contact

Name: Chris Smith

Address: 105 N 1st ST #429, SAN JOSE, CA 95103 US

E-mail: sales@credenceresearch.com

Ph: 1-800-361-8290

Web: http://www.credenceresearch.com